These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 3147279

  • 21. Increase in H-2 antigen expression and immunogenicity of BL6 melanoma cells treated with N-methyl-N'-nitronitrosoguanidine.
    Gorelik E, Peppoloni S, Overton R, Herberman RB.
    Cancer Res; 1985 Nov; 45(11 Pt 1):5341-7. PubMed ID: 2413992
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. H-2 antigen expression and sensitivity of BL6 melanoma cells to natural killer cell cytotoxicity.
    Gorelik E, Gunji Y, Herberman RB.
    J Immunol; 1988 Mar 15; 140(6):2096-102. PubMed ID: 3126240
    [Abstract] [Full Text] [Related]

  • 24. Identification of cellular mechanisms operational in vivo during the regression of established pulmonary metastases by the systemic administration of high-dose recombinant interleukin 2.
    Mulé JJ, Yang JC, Afreniere RL, Shu SY, Rosenberg SA.
    J Immunol; 1987 Jul 01; 139(1):285-94. PubMed ID: 3108401
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Defects in tumor cell immunogenicity: lymphokine signals in in vitro cytolytic responses to tumor alloantigens.
    Ashley MP, Kotlarski I, Vari F.
    Cell Immunol; 1987 Apr 15; 106(1):151-62. PubMed ID: 3568144
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Expression of H-2 antigens and inducibility of antitumor immune responses in various tumor cell clones established from methylcholanthrene-induced fibrosarcomas.
    Ogata M, Shimizu J, Kosaka H, Maekawa R, Shimizu K, Fujiwara H, Hamaoka T.
    Jpn J Cancer Res; 1986 Nov 15; 77(11):1134-41. PubMed ID: 3098723
    [Abstract] [Full Text] [Related]

  • 29. Mutagen-induced antigenic variants of tumor cells.
    Boon T, Van Pel A, De Plaen E, Vessière F.
    Symp Fundam Cancer Res; 1986 Nov 15; 38():139-48. PubMed ID: 3489258
    [No Abstract] [Full Text] [Related]

  • 30. In vivo and in vitro effect of adoptive immunotherapy of experimental murine brain tumors using lymphokine-activated killer cells.
    Takai N, Tanaka R, Yoshida S, Hara N, Saito T.
    Cancer Res; 1988 Apr 15; 48(8):2047-52. PubMed ID: 3258182
    [Abstract] [Full Text] [Related]

  • 31. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1996 Aug 15; 26(8):1851-9. PubMed ID: 8765031
    [Abstract] [Full Text] [Related]

  • 32. Cell-mediated immune responses to syngeneic tumors. I. Identification of two distinct CTL effector pathways which differ in antigen specificity, genetic regulation, and cell surface phenotype.
    Lynch DH, Daynes RA, Hodes RJ.
    J Immunol; 1986 Feb 15; 136(4):1521-7. PubMed ID: 2418117
    [Abstract] [Full Text] [Related]

  • 33. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
    Eggermont AM, Sugarbaker PH.
    Cancer Detect Prev; 1990 Feb 15; 14(4):483-90. PubMed ID: 2224911
    [Abstract] [Full Text] [Related]

  • 34. Generation of lymphokine-activated killer cells in strain 2 guinea pigs and their use in the therapy of L2C, an acute B-cell leukemia.
    Gregg EO, Gregg IC, Green I.
    Cancer Res; 1987 Feb 01; 47(3):723-9. PubMed ID: 3492265
    [Abstract] [Full Text] [Related]

  • 35. Alloantigen-induced cytotoxicity against syngeneic tumor cells: analysis at the clonal level.
    Sensi M, Orosz CG, Bach FH.
    J Immunol; 1984 Jun 01; 132(6):3218-25. PubMed ID: 6202778
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. [Studies on lymphokine-activated killer (LAK) cell: accumulation in tumor tissue and the therapeutic effects of adoptive immunotherapy].
    Wakizaka Y.
    Hokkaido Igaku Zasshi; 1992 Jul 01; 67(4):475-87. PubMed ID: 1330859
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.